Newsfile Corp
29 Jun 2026, 23:27 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
The Independent Data Monitoring Committee recommended the discontinuation of Immutep's Phase III TACTI-004 study for futility. — The failure of a late-stage clinical trial for a lead drug candidate typically results in a massive loss of company valuation and future revenue prospects.
-0.90A class action lawsuit has been filed alleging that Immutep misled investors regarding the viability and efficacy of its drug candidate. — Legal action and allegations of corporate misconduct create additional financial liability and reputational risk beyond the clinical failure.
-0.40Immutep's ADR price collapsed approximately 83% from $2.76 to $0.48 following the futility announcement. — While the price drop has already occurred, it confirms the market's severe devaluation of the company's current pipeline.
-0.20Which stocks this story touches
Continue reading
6 related stories
Top 3 movers · tap to explore
The company is facing a class action lawsuit and a massive stock price drop following the discontinuation of a Phase III clinical trial for futility.
The company is being urged by a law firm for stockholders to move for lead plaintiff, indicating ongoing shareholder litigation.
The company is being urged by a law firm for stockholders to move for lead plaintiff, indicating ongoing shareholder litigation.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Seeking Alpha
4h ago
